SL1-39

SL1-39 is a diarylthiourea analog of SHetA2, designed as a flexible heteroarotinoid (flex-het) with reduced lipophilicity (lower LogP) to improve clinical utility. Developed by researchers at Dominican University of California and Touro University of California, SL1-39 is being investigated as an anti-cancer agent for the treatment of estrogen receptor-negative (ER-) breast cancer. The compound exerts its anti-proliferative effects by down-regulating key cell cycle regulators, including cyclin A, cyclin B, cyclin D1, cyclin E, and cyclin-dependent kinase 2 (cdk2), which leads to a block in S-phase progression.

Other names

1-(4-chloro-3-methylphenyl)-3-(4-nitrophenyl)thiourea